Roche Diagnostics India launches heart failure test for diabetics as point-of-care device

Roche Diagnostics India announced the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF). This breakthrough innovation is designed to bring testing closer to clinics and revolutionise patient care.

The claim extension of the NT-proBNP biomarker, available exclusively on the ‘cobas h 232 ’ system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D).

Individuals with T2D and HF face up to an 8x increased risk of death compared to those without HF. Despite the number, approximately 80% of HF cases are only diagnosed following acute hospitalisaton, despite patients experiencing symptoms up to five years prior.  The challenge lies in the non-specific symptoms of HF, which often remain undetected until advanced stages. Recognising this critical gap, Roche Diagnostics India's NT-proBNP test on the ‘cobas® h 232 ’ system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions.

The incorporation of NT-proBNP test extension onto convenient point-of-care platforms is significant because this biomarker, when integrated into primary care settings, enables proactive assessment of heart failure risks in patients with T2D, thereby fostering improved outcomes and bolstering patient well-being.